Skip to main navigation Skip to search Skip to main content

Risks of Stimulant Use for Attention Deficit Hyperactivity Disorder on the Developing Brain: Primum non nocre.

  • East Tennessee State University
  • Harvard Medical School
  • Harvard University

Research output: Contribution to journalArticlepeer-review

Abstract

Excerpt: The prognosis of attention deficit hyperactivity disorder (ADHA) continues to "show heightened risk of multiple mental health and social difficulties as well as premature mortality in adult life" after nearly 50 years of primary pharmacological treatment. If the prognosis of ADHA is not changed by stimulants, then 2016 research that stimulants may cause cardiac arrhythmia and myocardial infarcation associated with subquent death in children younger than 17 years prescribed methylphenidate (MPH)^2 raises the question of whether stimulants should be used. Furthermore, a 2015 Cochran Review found 98.6% of ADHD randomized clinical trials could also have been considered high risk by using a stricter definition. ^3 Has medicalization and marketing of the diagnosis and treatment of ADHD become the basis of putting children at risk by using stimulants, especially in the United States?

Original languageAmerican English
JournalClinical Pediatrics
Volume56
DOIs
StatePublished - May 1 2017

Keywords

  • stimulant use
  • attention deficit hyperactivity disorder
  • developing brain
  • mental health
  • ADHD
  • development
  • pharmacological treatment
  • brain
  • primum non nocere

Disciplines

  • Pharmacy and Pharmaceutical Sciences

Cite this